NOVARESE,Inc. (9160) AI Stock Analysis

• Market Cap: ¥8.37B
• Dividend Yield: N/A
• Average Volume (3M): 21.72K
• Price to Earnings (P/E): 9.3
• Beta (1Y): 0.32
• Revenue Growth: 11.07%
• EPS Growth: 5.85%
• Country: JP
• Employees: 1,130
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Personal Products & Services
• EPS (TTM): 13.49
• Shares Outstanding: 25,073,093
• 10 Day Avg. Volume: 24,950
• 30 Day Avg. Volume: 21,720
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥372.00
• Price Target Upside: 11.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 72 Outperform
• Price Target: ¥372.00 ▲(11.04% Upside)

The overall stock score is driven primarily by a favorable valuation and positive technical indicators. While financial performance shows strong revenue growth, challenges with leverage and cash flow generation need addressing. The absence of earnings call data and corporate events does not impact the score significantly.

NOVARESE,Inc. Business Overview & Revenue Model

Company Description

NOVARESE, Inc. (9160) is a dynamic company operating in the biotechnology sector, specializing in the development and commercialization of innovative healthcare solutions. The company focuses on creating advanced therapeutics and diagnostic tools aimed at addressing unmet medical needs in various therapeutic areas, including oncology and rare diseases. NOVARESE leverages cutting-edge research and technology to enhance patient outcomes and improve overall health management.

How the Company Makes Money

NOVARESE, Inc. generates revenue primarily through the sale of its proprietary therapeutic products and diagnostic services. The company has established key revenue streams from direct product sales to healthcare providers and institutions, as well as licensing agreements with pharmaceutical companies for its patented technologies. Additionally, NOVARESE engages in strategic partnerships with research organizations and healthcare systems, which not only enhances its research capabilities but also opens up new markets and distribution channels. Government grants and funding for research initiatives also contribute to the company's financial health, allowing for sustained innovation and development.

NOVARESE,Inc. Financial Statement Overview

Summary

NOVARESE, Inc. demonstrates strong revenue growth and improving profitability metrics, though it faces challenges with high leverage and cash flow generation. The company is on a positive trajectory, but needs to address its debt levels and enhance cash flow stability to ensure long-term financial health.

Income Statement

NOVARESE, Inc. shows a solid revenue growth rate of 3.9% TTM, with consistent improvements in EBIT and EBITDA margins. However, the net profit margin remains modest at 4.1%, indicating room for profitability enhancement. The company has successfully increased its gross profit margin over time, reflecting efficient cost management.

Balance Sheet

The company's debt-to-equity ratio is relatively high at 2.29, suggesting significant leverage. However, the return on equity is improving, currently at 9.5%, indicating effective use of equity to generate profits. The equity ratio is moderate, showing a balanced asset structure.

Cash Flow

The free cash flow growth rate is negative at -8.8% TTM, indicating challenges in cash generation. The operating cash flow to net income ratio is healthy, suggesting good cash conversion, but the free cash flow to net income ratio indicates potential cash flow constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.53B	19.30B	18.27B	17.22B	11.19B	7.33B
Gross Profit	11.52B	10.86B	10.18B	10.14B	6.40B	3.40B
EBITDA	4.19B	3.82B	3.91B	4.93B	2.93B	-1.75B
Net Income	899.56M	663.90M	942.27M	1.66B	374.02M	-2.95B
Balance Sheet
Total Assets	34.52B	34.73B	32.30B	31.98B	32.63B	33.86B
Cash, Cash Equivalents and Short-Term Investments	2.40B	3.57B	1.72B	2.80B	2.25B	2.34B
Total Debt	14.34B	13.53B	19.01B	14.13B	22.31B	23.25B
Total Liabilities	25.44B	25.89B	24.12B	24.75B	27.04B	28.64B
Stockholders Equity	9.08B	8.85B	8.18B	7.23B	5.59B	5.22B
Cash Flow
Free Cash Flow	2.27B	2.50B	1.02B	3.26B	2.15B	-2.49B
Operating Cash Flow	3.93B	3.89B	3.00B	4.62B	2.37B	-912.07M
Investing Cash Flow	-1.81B	-1.45B	-2.03B	-1.34B	-253.64M	-1.58B
Financing Cash Flow	-2.39B	-621.47M	-2.04B	-2.73B	-2.21B	1.71B

NOVARESE,Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 335.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9160, the sentiment is Positive. The current price of 335 is below the 20-day moving average (MA) of 337.05, above the 50-day MA of 331.56, and above the 200-day MA of 312.36, indicating a neutral trend. The MACD of 1.08 indicates Positive momentum. The RSI at 49.71 is Neutral, neither overbought nor oversold. The STOCH value of 38.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9160.

NOVARESE,Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2485	74 Outperform	¥11.28B	9.31	―	4.03%	25.26%	65.66%
9160	72 Outperform	¥8.37B	9.30	―	―	11.07%	5.85%
2198	70 Outperform	¥23.30B	19.98	―	3.02%	-1.02%	-32.57%
4331	69 Neutral	¥12.06B	4.18	―	4.82%	0.81%	61.06%
2424	69 Neutral	¥3.71B	8.46	―	1.22%	6.57%	52.89%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
2196	57 Neutral	¥2.70B	21.34	―	―	-3.96%	-73.55%